Basit öğe kaydını göster

dc.contributor.authorUlutin, T.
dc.contributor.authorSaip, S.
dc.contributor.authorOzgon, G. Oner
dc.contributor.authorSiva, A.
dc.contributor.authorBuyru, N.
dc.contributor.authorLangaee, T. Y.
dc.contributor.authorfeng, h
dc.contributor.authorJohnson, J. A.
dc.contributor.authorHatemi, A. C.
dc.date.accessioned2021-03-05T19:42:33Z
dc.date.available2021-03-05T19:42:33Z
dc.date.issued2008
dc.identifier.citationOzgon G. O. , Langaee T. Y. , feng h., Buyru N., Ulutin T., Hatemi A. C. , Siva A., Saip S., Johnson J. A. , "VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, cilt.64, ss.889-894, 2008
dc.identifier.issn0031-6970
dc.identifier.otherav_d08f75c2-64fc-4636-9599-647ffc13f3aa
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/137870
dc.identifier.urihttps://doi.org/10.1007/s00228-008-0507-5
dc.description.abstractObjectives The objective of this study was to determine the quantitative influence of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP 2C9) polymorphisms on warfarin dose requirements in Turkish patients.
dc.language.isoeng
dc.subjectEczacılık
dc.subjectTemel Bilimler
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleVKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
dc.contributor.departmentState University System of Florida , ,
dc.identifier.volume64
dc.identifier.issue9
dc.identifier.startpage889
dc.identifier.endpage894
dc.contributor.firstauthorID26672


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster